

VIF World 2025 Agenda

Day 1 Mar. 20

Morning Plenary Session

0900 Plenary Panel: Revolutionizing Global Health: The Future of Vaccine Technology and Innovation

The global pandemic has accelerated innovation in vaccine development, pushing forward technologies like mRNA and viral vector platforms. As we move toward the next decade, the question remains: how can we ensure these breakthroughs continue to revolutionize healthcare globally? This panel will explore emerging vaccine platforms, personalized vaccines, and the role of AI in streamlining vaccine research.

0945 Plenary Panel: Global Vaccine Equity: Overcoming Challenges in Distribution and Access

While significant progress has been made in developing vaccines for diseases like COVID-19, achieving equitable distribution remains a challenge. This panel will focus on addressing global disparities in vaccine access, including the role of international cooperation, local manufacturing, and public-private partnerships.

1030 Tea Break

1100 Keynote: Innovative Vaccine Platforms: Accelerating Global Health R&D (TBD)

Francesco Berlanda Scorza, VP, R&D, Global Health R&D Vaccines Head and GVGH Institute Director, GSK, Italy

1125 Keynote: TBC

Dan Barouch, Professor, Harvard Medical School; Director, Center for Virology and Vaccine Research Beth Israel Deaconess Medical Center, USA

1150 Keynote: TBD

1230 Lunch

Contact us through sam.li@chstone-events.com or 86-13482341046

VIF World 2025 Agenda

Day 1 Mar. 20

Afternoon Session

Respiratory diseases/Flu/Covid	Cancer vaccine & immunotherapy	DCVMN Forum	Mucosal immunization
<p>Chair: Yuelong Shu, Director, Institute of Pathogen Biology, CAMS & PUMC, China</p> <p>1330 Pan-sarbecoV vaccine: a dream or reality? Linfa Wang, Professor, Duke-NUS Medical School, Singapore</p> <p>1355 TBC Peter L. Andersen, Chief Scientific Advisor, Infectious Diseases, Novo Nordisk Foundation, Denmark</p> <p>1420 TBC</p> <p>1445 TBC Wei Tan, SVP, Head of China Research and External Collaboration, Clover Biopharmaceutical, China</p> <p>1500 Clinical development for RSV vaccine in China (TBD) Zhaohua (Jessie) Chen, Head of Development China, General Manager of China R&D, Pfizer, China</p>	<p>1330 TBD David Weiner, EVP, The Wistar Institute, USA</p> <p>1355 Development of mRNA vaccines: from infectious diseases to oncology Ruben Rizzi, Senior Vice President Global Regulatory Affairs, BioNTech, Germany</p> <p>1420 TBC</p> <p>1445 TBC</p> <p>1510 Precision treatment of pancreatic cancer - personalized tumor treatment vaccine Landian Hu, CEO, Anda Biology Medicine Development (Shenzhen)</p> <p>1525 Tea Break</p> <p>1545 Therapeutic vaccine development for Cancer Bin Wang, Professor, Fudan University/Founder, Advaccine, China</p>	<p>1330 Strengthening Vaccine Manufacturing Capacity in Developing Countries: The Role of DCVMN Rajinder Suri, CEO, DCVMN International, Switzerland</p> <p>1355 Overview of HPV vaccine development and global vaccine introduction status Peter Dull, Deputy Director at Bill & Melinda Gates Foundation, USA</p> <p>Innovative Vaccine Platforms: Leveraging Global Collaboration for Pandemic Preparedness Raches Ella, Chief Development Officer, Bharat Biotech, India</p> <p>Building vaccine capability in Africa (TBC) Nicaise Ndembi, Head for Partnerships for African Vaccine Manufacturing (PAVM) & Head Science Office, Africa CDC, Ethiopia</p> <p>Development of the vaccine production facility and tech transfer in Latin America</p>	<p>Chair: Ling Chen, Professor, Guangzhou Laboratory, China</p> <p>Mucosal immunization represents a transformative approach to vaccine delivery, harnessing the immune system's natural defense mechanisms at mucosal surfaces to provide robust and long-lasting protection against infectious diseases. This half-day symposium at VIF World 2025 will bring together leading experts from academia, industry, and regulatory agencies to explore cutting-edge research, technological innovations, and translational strategies in mucosal immunization.</p> <p>The symposium will feature keynote presentations and panel discussions on:</p> <ol style="list-style-type: none"> Mechanisms of Mucosal Immunity: Innovative Delivery Platforms: Clinical Pipeline and Success Stories Regulatory and Manufacturing Perspectives

Contact us through sam.li@chstone-events.com or 86-13482341046

VIF World 2025 Agenda

<p>1525 Tea Break</p> <p>1545 TBC Linqi Zhang, Professor, Tsinghua University, China</p> <p>1610 TBC</p> <p>1700 Pan-Corona vaccine development (TBC) Shibo Jiang, Professor, Fudan University, China</p> <p>1730 End of session</p>	<p>1610 TBC</p> <p>1625 TBD Xiangrong Song, Cofounder& CEO, Westgene, China</p> <p>1640 Therapeutic HPV vaccine Ying Mazzu, COB&CSO, Nanjing AuroRNA Biotechnology, China</p> <p>1655 TBC</p> <p>1730 End of session</p>	<p>Adel Sattarova, Head of Project Management Department, FSUE SPbSRIVS FMBA of Russia</p> <p>Innovative products for low resource settings</p> <p>Melanie Saville, CSO, PATH, USA</p>	<p>Speakers: Ling Chen, Professor, Guangzhou Laboratory, China Tao Zhu, CSO, CanSino, China Hong Jin, CSO, CynVac, USA Chunlai Jiang, EVP, Changchun BCHT Biotech, China Huiming Yan, Professor, Fudan University, China Ningshao Xia, Professor, Xiamen University, China Rita Carsetti, VP, International Union of Immunological Societies; Professor, Bambino Gesù Children Hospital, Italy</p>
<p>1830 Welcome reception (Invited only)</p>			

Contact us through sam.li@chstone-events.com or 86-13482341046

VIF World 2025 Agenda

Day 2 Mar. 21

Morning Session

Biomanufacturing & Formulation	Emerging & Re-emerging	Vaccine Design and Preclinical	RNA Technologies
<p>0900 Building Sustainable Local Vaccine Manufacturing: WHO's Support for Low-Resource Settings Jicui Dong, Unit Head, Local Production & Assistance Unit, Innovation and Emerging Technologies Department (IET),MHP, World Health Organization, Switzerland</p> <p>0925 Advanced technology platforms for vaccine manufacturing in response to pandemic situations Amine Kamen, Professor, McGill University, Canada</p> <p>0950 Next-Generation Vaccine Manufacturing: Scaling Innovation for Global Health (TBD) Jian Dong, CEO, WuXi Vaccines; SVP, WuXi Biologics, China</p> <p>1020 TBC</p> <p>1035 Tea Break</p>	<p>0900 Malaria Vaccines: from Licensure to Elimination Adrian V. S. Hill, Director, The Jenner Institute, Lakshmi Mittal & Family Professor of Vaccinology, University of Oxford , UK</p> <p>0925 Rational design of Zika vaccine to eliminate dengue enhancement Lianpan Dai, Professor, Institute of Microbiology, Chinese Academy of Sciences, China</p> <p>0940 Innovative immunogen design for mpox virus vaccine development Han Wang, Associate Professor, Peking University, China</p> <p>0955 TBC</p> <p>1020 Rationale, progress and opportunities for the development of next generation rotavirus vaccines Baoming Jiang, Professor, CDC, USA</p>	<p>Chair: Shaowei Li, Professor, Xiamen University, China</p> <p>0900 Structure-Based Vaccine Design: Innovations in Stabilizing Antigens and Addressing Emerging Viral Threats Jason McLellan, Professor, University of Texas at Austin, USA</p> <p>0925 AI-Guided and Structure-Based Vaccine Design George Fu Gao, Former Director, China CDC; Professor, Chinese Academy of Sciences, China</p> <p>0950 TBC</p> <p>1015 TBC Tongqing Zhou, Chief, Structural Bioinformatics Section National Institutes of Health, USA</p>	<p>0900 Lipid nanoparticles for mRNA vaccine delivery Pardi Norbert, Associate Professor, University of Pennsylvania, USA</p> <p>0925 mRNA Vaccines in Low- and Middle-Income Countries: Bridging the Gap Kiat Ruxrungham, Professor of Medicine, Director of Chula VRC, Chulalongkorn University, Thailand</p> <p>0950 TBC</p> <p>1020 RNA platform implementation in Brazil: Seeding the innovation ecosystem in Latin America Patrícia Neves, Project Manager, mRNA center,Bio-Manguinhos/ Fiocruz, Brazil</p> <p>1035 Tea break</p> <p>1100mRNA vaccines and global health: addressing global unmet needs in infectious diseases Ruben Rizzi, Senior Vice President Global</p>

Contact us through sam.li@chstone-events.com or 86-13482341046

VIF World 2025 Agenda

1100 Next-Generation Vaccine Platforms: Innovations in Process Development (TBD)

Hao Chen, AVP, Head of Vaccines & Advanced Biotechnologies Process R&D, Merck, USA

1035 Tea break

1100 TBC

1115 6-Valent Virus-Like Particle-Based Vaccine development against Norovirus

Dongming Zhou, Head of R&D, Chengdu Kanghua Biological Products Co., China (Invited)

1130 TBC

1200 Assembly of Virus-like Particles Harnessed with RNA-based Chaperone

Baik-Lin Seong, Director General, Vaccine Innovative Technology Alliance (VITAL)-Korea, South

1215 A quadrivalent mRNA vaccine candidate elicited potent immune responses against monkeypox virus and protection in a rodent model

Yelin Xiong, VP, Yither Biotech, China

1230 Lunch

1035 Tea Break

1100 Next-Generation Vaccine Platforms: A Blueprint for Global Preparedness (TBD)

Ken Ishii, Director, International Vaccine Design Center, Professor, University of Tokyo, Japan

1125 TBD

Qihan Li, Professor, Weirui Bio, China

1150 TBD

Yoshimasa Takahashi, Director, Research Center for Drug and Vaccine Development, National Inst. of Infectious Diseases, Japan

1215 TBC

1230 Lunch

Regulatory Affairs, BioNTech, Germany

1125 Reserved by NanoFCM

1155 TBD

Heinrich Hass, CTO, NeoVac, UK

1210 Enhancing the potency of RNA vaccines through next-generation modifications

Kate Broaderick, Chief Innovation Officer, Maravai Life Sciences, USA

1230 Lunch

Contact us through sam.li@chstone-events.com or 86-13482341046

VIF World 2025 Agenda

Biomanufacturing & Formulation	Clinical trial	Vaccine Tech Innovation	RNA Technologies
<p>Chair: Joon Haeng Rhee, Professor, Chonnam National University Medical School, South Korea Dexiang Chen, CEO, Maxvax, China</p> <p>Nanotechnology in Vaccine Development: Transforming Delivery and Efficacy Chunying Chen, Academician, Professor, The National Center for Nanoscience and Technology, CAS, China</p> <p>Optimizing Vaccine Adjuvants: Bridging Immunology and Global Vaccine Development Arnaud Didierlaurent, Assistant Professor, Center Director of Vaccinology, University of Geneva, Switzerland</p> <p>Enhancing Mucosal Immunity with RAR Agonists as Potent Vaccine Adjuvants Haibo Li, Professor, Army Medical University</p> <p>Harnessing the power of TLR agonists as vaccine adjuvants Nikolai Petrovsky, Founder, Vaxine, Australia</p>	<p>1330 TBD Jingxin Li, Vice Director of the Department, Jiangsu CDC, China</p> <p>1355 TBC</p> <p>1410 Reduced dose HPV vaccine development Ting Wu, Professor, Xiamen University (TBC)</p> <p>1435 Clinical trial for Maternal vaccine development TBC</p> <p>1500 Clinical strategy for the immunocompromised TBC</p> <p>1530 Tea Break</p> <p>1600 Vaccine clinical development strategy in emerging market(s) and Commercial potentials Adham Rezk, CEO, Celero Global, Singapore</p>	<p>1330 Innovative Delivery Methods for Next-Generation Vaccines: Nasal, Inhalable, and Beyond SeyedReza Banihashemi, Director of R&D, Razi Vaccine & Serum Research Institute, Iran</p> <p>1345 The Molecular Clamp Platform: A broadly applicable solution to the manufacture of multivalent subunit vaccines for respiratory viruses Keith Chappel, Group Lead, The university of Queensland, Australia</p> <p>1400 TBC</p> <p>1430 Innovating Plant-Based Vaccines: A New Frontier in Global Health Suthira Taychakhoonavudh, CEO, Baiya Phytopharm, Thailand</p> <p>1445 TBD Deog-Young Choi, CEO, InThera, South Korea</p> <p>1500 TBC</p>	<p>1330 Revolutionizing Therapeutics with Next-Generation RNA Platforms: From Vaccines to Gene Therapy(TBD) Zihao Wang, CEO, Immorna Bio, China</p> <p>1345 Expanding the Frontier: mRNA Vaccines for Cancer and Autoimmune Diseases(TBD) Bo Ying, Co-founder, Chairman&CEO, Abogen Biosciences, China</p> <p>1400 TBC</p> <p>1430 TBC</p> <p>1500 Non-reactogenic LNPs addressing mRNA vaccination hesitancy Jiangsheng Xu, Co-founder&CSO, General Therapeutics, USA</p> <p>1515 Next-Generation Lipid Nanoparticle Systems for Targeted RNA Delivery Xuexiang Han, Professor, SIBCB, China</p> <p>1530 Tea Break</p> <p>1600 TBC</p>

Contact us through sam.li@chstone-events.com or 86-13482341046

VIF World 2025 Agenda

<p>TBD</p>		<p>1515 Amezosvatein Phase 2 trial results George Simeon, CEO, Curevo Vaccine, USA</p> <p>1530 Tea Break</p> <p>1600 Revolutionizing Pneumococcal Vaccination: Advancing Towards a Universal Pneumococcal Vaccine Solution Tim Hirst, CEO, GPN Vaccines, Australia</p> <p>1615 TBC</p> <p>1630 TBC Yasuo Yoshioka, Project Lead, BIKEN, Japan</p>	<p>1630 Optimizing Tissue Distribution & Safety of LNP-Mediated Prophylactic Vaccines to Accelerate Prevention of Infection & Disease Hui Li, R&D Director, Innorna, China</p> <p>1645 TBC</p> <p>1700 Panel discussion</p>
------------	--	---	---

1830 Cocktail Party (Invited)

Day 3 Mar. 22

Morning Session

AMR	Veterinary Vaccine	Preclinical Immunobiology	Partnership & Market access
<p>0900 Revolutionizing Vaccine Development: Lessons from a Lifetime in</p>	<p>0900 Innovations in Veterinary Biologics: Navigating the Future of Animal Health</p>	<p>0900 Innate Immunity and Vaccine Adjuvant Innovation: Leveraging the Body's</p>	<p>Hun Kim, President of Global Biz, SK bioscience, South Korea</p>

Contact us through sam.li@chstone-events.com or 86-13482341046

VIF World 2025 Agenda

<p>Immunology George Siber, President, Siber Biotechnologies LLC, USA</p> <p>0925 Tackling Maternal and Neonatal Infections: The Role of Group B Streptococcus Vaccines" Per Fischer, CEO, MinervaX, Denmark (Invited)</p> <p>0940 Immunotherapy and Vaccine Synergy: A New Frontier in Infectious Disease Treatment Bruno Santos, CEO, Immunethep, Portugal (Invited)</p> <p>0955 Pioneering New Horizons in Bacterial Vaccines: From Concept to Clinical Application Michael Kowarik, Co-Founder & Chief Scientific Officer, LimmaTech, Switzerland (Invited)</p> <p>1010 TBC</p> <p>1035 Tea break</p> <p>1100 Isolation of protective monoclonal antibodies and development of novel fusion protein vaccines against tuberculosis</p>	<p>Mahesh Kumar, SVP of R&D, Global Biologics, Zoetis, USA</p> <p>0925 Cross-Species Transmission of Animal Viruses: Prevention and Control Strategies Simon Graham, Professor, The Pirbright Institute, UK</p> <p>0950 Immunological Insights into Animal Disease Control: A Path Toward Enhanced Vaccine Efficacy Huichen Guo, Professor, Lanzhou Veterinary Research Institute, China</p> <p>1015 TBC</p> <p>1035 Tea Break</p> <p>1100 Advancing ASFV Vaccine Development: Overcoming the Challenges in Combatting African Swine Fever Christopher Netherton, Professor, The Pirbright Institute, UK</p> <p>1125 Revolutionizing Animal Vaccine Development: The Role of mRNA and Exosome Platforms Jie Li, Head of R&D, The Spirit Jinyu Biological Pharmaceutical, China</p> <p>1140 Progress on the ASF DNA vaccine development in Philippines</p>	<p>First Line of Defense Diana Boraschi, Distinguished Professor, Shenzhen Institute of Advanced Technology, China</p> <p>0925 Vaccine adjuvants, mRNA mode of action, innate/trained immunity for vaccines Robbert van der Most, Former VP, , BioNTech; CEO, VaxxCelence, Germany</p> <p>0950 Bioassay for vaccine efficacy Emanuel Montomoli, Professor, Full Prof. of Public Health, University of Siena;CSO of VisMederi Italy</p> <p>1005TBC Yunlong Richard Cao, Assistant Professor, Peking University, China</p> <p>1030 Tea Break</p> <p>1100 TBC</p> <p>1130 Immunogenicity testing of pan-variant influenza and coronavirus vaccines using pseudotype platform technologies Nigel Temperton, Professor, Director, Viral Pseudotype Unit, University of Kent, UK</p>	<p>Raman Rao, CEO, the Hilleman Laboratories, Singapore</p> <p>Meng Li, Head of Board Office, Director of International Cooperation, China National Biotec Group, China</p> <p>Xiaofeng Liang, VP, Chinese Preventive Medicine Association; Professor, Jinan University, China</p> <p>Nibal Dahaba, Co-Founder & General manager Emerging markets, Gennecs Holding, Egypt</p> <p>Jiguo (Jeffrey) Zhang, President, Vaccine Division, Fosun Pharma, China</p> <p>Hani Kim, Executive Director, RIGHT Foundation, South Korea</p> <p>Sean Du, Head, External R&D APAC, Global R&D, Sanofi Pasteur, China</p>
--	---	---	---

Contact us through sam.li@chstone-events.com or 86-13482341046

VIF World 2025 Agenda

Hao Li, Associate Professor, China Agricultural University, China

1115 Harnessing mRNA Technology to Combat Antimicrobial Resistance: Pioneering Vaccines for Drug-Resistant Bacteria

Caiyi Fei, VP, TheraRNA, China

1130 TBC

1200 TBC

1230 Lunch

Frank Chang, CSO, Reber Genetics, China

1155 TBC

1230 Lunch

1330 Advancing One Health: Integrating Veterinary and Human Vaccines to Tackle Global Health Challenges

Alejandra Capozzo, Professor, Center Director, Universidad Abierta Interamericana (UAI), Argentina

1355 The development of PDCoV and PEDV mRNA vaccines

Zhong Chen, VP, Suzhou HealiRNA Biotechnology

1145 Antigenic sin drives B cell evolution: lessons learned from the COVID-19 pandemic

Emanuele Andreano, Project Leader, Fondazione Toscana Life Sciences, Italy

1230 Lunch

Plenary Session

1530 Plenary Panel: Vaccines Beyond Borders: Shaping Global Health Futures in an Interconnected World

"Vaccines Beyond Borders: Shaping Global Health Futures in an Interconnected World"

This dynamic panel will serve as a grand finale for VIF World 2025, uniting thought leaders from academia, industry, public health, and policy to address the evolving role of vaccines in a rapidly changing global landscape. The discussion will focus on:

1. Global Collaboration and Equity: Exploring innovative strategies to ensure equitable vaccine access and distribution, especially in underserved regions.
2. One Health and Pandemic Preparedness: Highlighting the interconnectedness of human, animal, and environmental health and the role of vaccines in preventing future pandemics.
3. Technological Breakthroughs: Reflecting on the transformative potential of mRNA, mucosal, and nanoparticle-based vaccines to combat emerging and re-emerging infectious diseases.
4. Policy and Funding Innovations: Discussing sustainable funding models and global governance frameworks to accelerate vaccine innovation and deployment.
5. Vision for 2030 and Beyond: Imagining a future where vaccines play a central role in addressing not only infectious diseases but also broader challenges like antimicrobial resistance,

Contact us through sam.li@chstone-events.com or 86-13482341046

VIF World 2025 Agenda

chronic diseases, and aging populations.

The plenary will feature a diverse and influential panel, including representatives from leading vaccine manufacturers, global health organizations, policymakers, and scientific pioneers. By engaging the entire audience in this visionary discussion, the session will inspire actionable insights, foster global collaboration, and leave participants energized to drive meaningful change in the vaccine landscape.

1630 Closing Remark

Contact us through sam.li@chstone-events.com or 86-13482341046